CME Group Inc.

NasdaqGS:CME Stok Raporu

Piyasa değeri: US$105.1b

CME Group Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 4/6

CME Group yıllık ortalama 12.5% oranında kazançlarını artırırken, Capital Markets sektöründe kazançlar growing at 6.1% annual. Gelirler growing yılda ortalama 8.5% oranında artmaktadır. CME Group'in özkaynak karlılığı 16% ve net marjı 62.9%'dir.

Anahtar bilgiler

12.55%

Kazanç büyüme oranı

12.46%

EPS büyüme oranı

Capital Markets Sektör Büyümesi10.26%
Gelir büyüme oranı8.55%
Özkaynak getirisi16.04%
Net Marj62.95%
Son Kazanç Güncellemesi31 Mar 2026

Yakın geçmiş performans güncellemeleri

Recent updates

Anlatı Güncellemesi May 15

CME: Mixed Street Views And New Markets Will Shape Future Earnings Power

Narrative Update on CME Group The analyst price target for CME Group has been trimmed by about $2, reflecting updated views on slightly softer revenue growth and a modestly lower future P/E multiple. At the same time, some analysts highlight areas of support such as commodities volumes as well as agriculture and prediction markets.
Anlatı Güncellemesi Apr 27

CME: Volatile Street Views And New Futures Will Shape Trading Mix

Analysts have nudged their fair value estimate for CME Group down to $308.20 from $311.67, reflecting slightly softer revenue growth assumptions and a higher discount rate, partly balanced by a higher projected profit margin and a modestly lower future P/E, in line with the mix of recent price target trims and increases across the Street. Analyst Commentary Recent Street research on CME Group has been active on both sides, with several firms adjusting price targets and ratings in different directions.
Seeking Alpha Apr 23

CME Group Q1 Earnings Show Strength, But The Stock Still Looks Expensive

Summary CME Group delivered record Q1 volumes and revenue but missed consensus EPS and revenue estimates by narrow margins. CME remains a hold; the stock’s premium valuation already prices in strong volumes, steady cash flows, and its competitive moat. Growth is driven by diverse product expansion, including commodities, crypto, and cross-margining, but near-term upside is limited absent a volatility or trading surge. Key risks are volume normalization, regulatory changes, and tech disruptions; current price fairly reflects both strengths and risks. Read the full article on Seeking Alpha
Anlatı Güncellemesi Apr 11

CME: Volatility And New Contracts Will Shape Rare Earths And Crypto Volumes

The updated analyst price target for CME Group has moved higher by about $5 to $311.67. This change reflects analysts' use of a slightly lower discount rate, a modestly higher assumed revenue growth rate, and a marginally higher future P/E multiple, even as they factor in a small trim to projected profit margins.
Anlatı Güncellemesi Mar 26

CME: Volatility And New Contracts Will Shape Rare Earths And Volume Mix

Analysts have made a modest upward adjustment to the CME Group fair value estimate to about $307 from roughly $305, reflecting slightly revised assumptions for discount rate, revenue growth, profit margin, and future P/E following a mix of recent rating changes and price target tweaks across the Street. Analyst Commentary Recent research on CME Group reflects a mixed but generally balanced backdrop, with several firms adjusting ratings and price targets in different directions.
Anlatı Güncellemesi Mar 11

CME: Volatility And New Contracts Will Shape Rare Earths And Clearing Outlook

Our analyst price target for CME Group has moved modestly higher to $305.21 from $299.29, as analysts factor in slightly stronger modeled revenue growth and profitability. This is partially offset by a more conservative future P/E assumption and mixed views on volume drivers across product lines.
Anlatı Güncellemesi Feb 25

CME: Volatility And New Contracts Will Shape Futures And Clearing Outlook

The analyst price target for CME Group edges higher to $232, with recent updates reflecting analysts' focus on firmer commodities volumes, as well as a more expense conscious outlook in their refreshed earnings models. Analyst Commentary Recent Street research around CME Group reflects a mix of optimism on volumes and earnings power, alongside caution on valuation and the cost base.
Anlatı Güncellemesi Feb 10

CME: Volatility And Prediction Markets Will Guide Futures And Clearing Expansion Outlook

The updated analyst price target for CME Group edges higher to about US$297 from roughly US$290, reflecting analysts' use of a slightly lower discount rate, a modestly higher assumed revenue growth rate, and a similar future P/E multiple despite a slightly lower profit margin input. Analyst Commentary Street research on CME Group in recent sessions centers on a cluster of revised price targets and at least one rating change, with several bullish analysts lifting their targets by varying dollar amounts and one major bank fine tuning its view in both directions over a short time frame.
Anlatı Güncellemesi Jan 27

CME: Volatility And Prediction Markets Will Shape Futures Activity Outlook

The analyst price target for CME Group is now US$290.40, a move of about US$2 from the prior US$288.33, as analysts factor in slightly different assumptions for fair value, discount rate, revenue growth, profit margins, and future P/E following mixed recent research that includes both a modest target cut and an upgrade linked to a tilt toward volatility. Analyst Commentary Recent research on CME Group reflects a mix of optimism and caution, with one firm trimming its price target slightly and another upgrading the stock on what it sees as a better setup for volatility related trading activity.
Anlatı Güncellemesi Jan 12

CME: Fee Moat And Prediction Markets Will Shape Futures Activity Outlook

Narrative Update: CME Group CME Group's fair value estimate has edged up by about $1 to roughly $288 per share, as analysts cite the company's strong futures and options moat, a higher price target range of up to $314, and interest in its role within prediction markets as key supports for the updated outlook. Analyst Commentary Recent Street research has been generally constructive on CME Group, with several bullish analysts adjusting their price targets higher and highlighting the company's futures and options franchise as a key support for valuation.
Anlatı Güncellemesi Dec 27

CME: Fee Resilience And Prediction Markets Will Balance Lower Volatility Risks

Analysts have nudged their average price target on CME Group modestly higher, to approximately $287 from about $286, citing the company’s resilient fee-based revenue mix, strong competitive moat in futures and options, and supportive demand signals from prediction market partnerships despite some conflicting views on near term volume volatility. Analyst Commentary Recent Street research presents a mixed but generally constructive view on CME Group, with upward moves in price targets tempered by concerns around volume sensitivity and valuation risk if volatility normalizes.
Anlatı Güncellemesi Dec 13

CME: Fee Resilience And New Prediction Markets Will Help Navigate Volatility

Analysts have raised their fair value estimate for CME Group by about $1 to roughly $286 per share, citing the company’s resilient clearing and transaction fee driven revenue base, modestly higher long term growth expectations, and a reinforced competitive moat highlighted in recent target revisions across the Street. Analyst Commentary Street research on CME Group reflects a wide range of views on valuation and execution, with recent target changes clustering around expectations for resilient fee income but diverging on the sustainability of growth and the impact of lower volatility.
Anlatı Güncellemesi Nov 16

CME: Revenue Resilience And New Ventures Will Balance Volatility Risks Ahead

The average analyst price target for CME Group was raised by approximately $3 to $285, as analysts point to the firm's resilient revenue streams and strong market position amid continued macroeconomic uncertainty. Analyst Commentary Recent analyst activity reflects a mix of optimism and caution regarding CME Group's performance and outlook, particularly as the firm navigates shifting macroeconomic and market conditions.
Seeking Alpha Apr 27

CME: More Market Volatility Equals More Demands - Initiating With Strong Buy

Summary Initiating a 'Strong Buy' rating for CME with a fair value of $301 per share due to increased demand for hedging amid economic uncertainty and market volatility. CME's diverse product offerings and strong trading volume growth, particularly in interest rate options/futures, equity, FX, energy, and commodities, support its robust business model. CME's high operating margin, capex-light business model, and strategic use of Google Cloud enhance profitability and operational efficiency. Key risks include potential pushback on market data price increases and competition from FMX Futures Exchange in the US treasury market. Read the full article on Seeking Alpha
Seeking Alpha Mar 27

CME Group At A New All-Time High - Valuation Concerns Justified?

Summary CME shares have delivered market-beating returns over the past two years, prompting the question of whether it's time to lock in profits. In this update, I discuss whether the rally appears sustainable against the backdrop of the 2024 results published in mid-February. The analysis focuses on average contract volumes and rates, signs of potential underinvestment given the surprisingly strong free cash flow, and includes an update on debt and leverage. I explain why I do not intend to sell my CME stock position despite the elevated valuation, and why I am not even considering a covered call strategy at this time. Read the full article on Seeking Alpha
Seeking Alpha Feb 18

CME Group: High Quality With Good Dividend Yield

Summary CME Group's near-monopoly in futures and options trading, with extraordinary 60% FCF margins, makes it a high-quality, capital-light business despite regulatory costs. Significant acquisitions like CBOT, NYMEX, and KCBT have solidified CME's market dominance, though future focus will be on dividends and smaller acquisitions. CME is slightly undervalued with a 4% dividend yield, making it a strong hold for dividend-focused investors seeking a high-quality business model. Read the full article on Seeking Alpha

Gelir ve Gider Dağılımı

CME Group nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NasdaqGS:CME Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
31 Mar 266,7444,2451,7900
31 Dec 256,5074,0211,7510
30 Sep 256,3853,7171,6950
30 Jun 256,4333,7211,6810
31 Mar 256,2743,5811,6540
31 Dec 246,1203,4821,6460
30 Sep 246,0343,4221,6300
30 Jun 245,7883,2621,5900
31 Mar 245,6163,1571,5770
31 Dec 235,5793,1861,5150
30 Sep 235,3383,0111,5360
30 Jun 235,2282,9421,5190
31 Mar 235,1042,8281,4910
31 Dec 225,0192,6571,3990
30 Sep 224,8332,6331,4430
30 Jun 224,7152,8891,4400
31 Mar 224,6572,7451,4480
31 Dec 214,6902,6171,4180
30 Sep 214,6302,4351,5210
30 Jun 214,6001,9201,5430
31 Mar 214,6031,9131,5640
31 Dec 204,8842,1051,4910
30 Sep 204,9112,1511,5450
30 Jun 205,1092,3751,5390
31 Mar 205,2002,3861,5320
31 Dec 194,8682,1171,4470
30 Sep 194,9592,0331,5180
30 Jun 194,5881,8081,3700
31 Mar 194,3771,8601,2350
31 Dec 184,3091,9621,1260
30 Sep 183,9734,5169770
30 Jun 183,9594,4139960
31 Mar 183,8244,2629930
31 Dec 173,6454,0639290
30 Sep 173,6581,4981,0140
30 Jun 173,6091,6621,0000
31 Mar 173,5901,5661,0080
31 Dec 163,5951,5349710
30 Sep 163,4961,4529840
30 Jun 163,5051,3409940
31 Mar 163,4181,2849860
31 Dec 153,3271,2479850
30 Sep 153,3541,2629980
30 Jun 153,2661,1929850

Kaliteli Kazançlar: CME yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: CME 'nin mevcut net kar marjları (62.9%) geçen yılın (57.1%) sinden daha yüksektir.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: CME şirketinin kazancı son 5 yılda yılda 12.5% oranında arttı.

Büyüme Hızlandırma: CME 'un son bir yıldaki kazanç büyümesi ( 18.5% ) 5 yıllık ortalamasını (yıllık 12.5% ) aşıyor.

Kazançlar vs. Sektör: CME geçen yılki kazanç büyümesi ( 18.5% ) Capital Markets sektörünün 37.2% performansını geride bırakmadı.


Özkaynak Getirisi

Yüksek ROE: CME 'nin Özsermaye Getirisi ( 16% ) düşük olarak değerlendiriliyor.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/21 11:25
Gün Sonu Hisse Fiyatı2026/05/21 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

CME Group Inc. 34 Bu analistlerden 13, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Stephen BiggarArgus Research Company
Benjamin BudishBarclays
Roger FreemanBarclays